# Generating implementation evidence in clinical trials of vaccines and immunization-related technologies to reduce evidence-to-policy delays

## TL;DR

This paper suggests integrating implementation research into vaccine clinical trials to speed up the adoption of new vaccines by providing practical evidence for policymakers.

## Contribution

The novel contribution is proposing a framework to systematically generate policy-relevant implementation evidence during vaccine clinical trials.

## Key findings

- Implementation evidence alongside efficacy outcomes can reduce evidence-to-policy delays.
- Interdisciplinary collaboration and engagement with policymakers are crucial for successful implementation research.
- A framework is proposed to guide the integration of implementation science into vaccine development.

## Abstract

Evidence-to-policy delays pose a significant threat to the timely adoption of novel vaccine products despite their proven efficacy. Understanding the “how to” (i.e., implementation aspects) of innovative vaccine products can facilitate decision-making to fast-track prioritization and introduction. This perspective highlights the need to integrate implementation research within clinical trials of vaccines and immunization-related technologies to facilitate the generation of policy-relevant implementation evidence. We argue that implementation context, mechanisms, strategies, adaptation, and transportability should be systematically reported alongside efficacy outcomes to support decision-makers in informing policies regarding their use in routine settings. We propose a framework for embedding implementation research in vaccine development and advocate for stronger collaborations between research teams and policymakers. The success of implementation research within clinical trials of vaccine products depends on interdisciplinary expertise, proactive decision-maker engagement, and adherence to relevant implementation science reporting guidelines.